SCHEMBL7568401

SCHEMBL7568401

N#Cc1cccc(NN=C(Cl)C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 2/20 0.43
HSD17B10 Q99714 2/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CISD1 Q9NZ45 1/20 0.43
IDO1 P14902 1/20 0.42
SLC22A12 Q96S37 1/20 0.41
GRM4 Q14833 1/20 0.41
ABCC9 O60706 1/20 0.40
KCNJ11 Q14654 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7644896 1.00 PDK1 (0.46) PDK1PDK2PDK3PDK4MAPT
SCHEMBL7567499 0.82 PDK1 (0.46) PDK1PDK2PDK3PDK4MAPT
SCHEMBL3833229 0.82 PDK1 (0.46) PDK1PDK2PDK3PDK4MAPT
SCHEMBL25888267 0.82 PDK1 (0.49) PDK1PDK2PDK3PDK4MAPT
SCHEMBL7562474 0.79 MAPT (0.43) PDK1PDK2PDK3PDK4MAPT
SCHEMBL5442762 0.75 GRM4 (0.43) MAPTMEN1KMT2AALDH1A1ALOX15
SCHEMBL8359213 0.75 GRM4 (0.43) MAPTMEN1KMT2AALDH1A1ALOX15
SCHEMBL7571560 0.75 PDK1 (0.45) PDK1PDK2PDK3PDK4MAPT
SCHEMBL7568763 0.75 PDK1 (0.45) PDK1PDK2PDK3PDK4MAPT
SCHEMBL7564392 0.73 MAPT (0.43) PDK1PDK2PDK3PDK4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6465656-B2 ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-15 US disclosed
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 US disclosed
US-6329527-B1 ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles TFPI, SERPINC1, F11 PDK1 451/4885PDK2 181/4885PDK3 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.